NASDAQ:RDUSRadius Health Stock Price, Forecast & News

Radius Health's stock was trading at $16.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, RDUS stock has decreased by 23.7% and is now trading at $12.25. View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Radius Health in the last year. There are currently 5 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Radius Health.

Radius Health is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Radius Health.

Radius Health Inc (NASDAQ:RDUS) released its earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.72) by $0.09. The biopharmaceutical company had revenue of $47.92 million for the quarter, compared to the consensus estimate of $46.77 million. Radius Health had a negative net margin of 66.82% and a negative return on equity of 929.94%. View Radius Health's earnings history.

Radius Health updated its FY 2020 After-Hours earnings guidance on Thursday, May, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $190-220 million, compared to the consensus revenue estimate of $225.56 million.

8 brokerages have issued twelve-month price targets for Radius Health's shares. Their forecasts range from $20.00 to $40.00. On average, they anticipate Radius Health's share price to reach $28.14 in the next twelve months. This suggests a possible upside of 129.7% from the stock's current price. View analysts' price targets for Radius Health.

News coverage about RDUS stock has trended negative on Saturday, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Radius Health earned a media sentiment score of -2.8 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the stock's share price in the near future. View the latest news aboutRadius Health.

Some companies that are related to Radius Health include Ra Pharmaceuticals (RARX), TG Therapeutics (TGTX), Prestige Consumer Healthcare (PBH), Principia Biopharma (PRNB), Pacira Biosciences (PCRX), Ligand Pharmaceuticals (LGND), Eidos Therapeutics (EIDX), IGM Biosciences (IGMS), SAGE Therapeutics (SAGE), Passage Bio (ZNTL), Epizyme (EPZM), Zymeworks (ZYME), Madrigal Pharmaceuticals (MDGL), Aurinia Pharmaceuticals (AUPH) and Heron Therapeutics (HRTX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Radius Health investors own include NVIDIA (NVDA), Gilead Sciences (GILD), EXACT Sciences (EXAS), Cara Therapeutics (CARA), Amarin (AMRN), Opko Health (OPK), Portola Pharmaceuticals (PTLA), Netflix (NFLX), ACADIA Pharmaceuticals (ACAD) and Micron Technology (MU).

Radius Health trades on the NASDAQ under the ticker symbol "RDUS."

Radius Health's stock is owned by a number of retail and institutional investors. Top institutional shareholders include State Street Corp (5.04%), Emerald Mutual Fund Advisers Trust (1.61%), Geode Capital Management LLC (1.45%), Nuveen Asset Management LLC (1.19%), Two Sigma Advisers LP (1.05%) and Pictet Asset Management Ltd. (0.92%). Company insiders that own Radius Health stock include Anthony Rosenberg, Debasish Roychowdhury, Growth N V Biotech, Jessica Hopfield, Joseph Francis Kelly, Target N V Biotech and Willard H Dere. View institutional ownership trends for Radius Health.

RDUS stock was sold by a variety of institutional investors in the last quarter, including Mackay Shields LLC, First Trust Advisors LP, Two Sigma Investments LP, Spark Investment Management LLC, Chicago Equity Partners LLC, Tudor Investment Corp Et Al, Congress Park Capital LLC, and Squarepoint Ops LLC. View insider buying and selling activity for Radius Health.

RDUS stock was purchased by a variety of institutional investors in the last quarter, including Tang Capital Management LLC, Nuveen Asset Management LLC, Rhenman & Partners Asset Management AB, Russell Investments Group Ltd., Janus Henderson Group PLC, Pictet Asset Management Ltd., Two Sigma Advisers LP, and MERIAN GLOBAL INVESTORS UK Ltd. Company insiders that have bought Radius Health stock in the last two years include Growth N V Biotech, Jessica Hopfield, Joseph Francis Kelly, and Target N V Biotech. View insider buying and selling activity for Radius Health.

Shares of RDUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of RDUS stock can currently be purchased for approximately $12.25.

Radius Health has a market capitalization of $568.27 million and generates $173.32 million in revenue each year. The biopharmaceutical company earns $-132,990,000.00 in net income (profit) each year or ($2.89) on an earnings per share basis. Radius Health employs 398 workers across the globe.

The official website for Radius Health is www.radiuspharm.com.

Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-551-4000 or via email at [email protected]